Analysis of Scope and Claims for U.S. Patent 7,250,419
U.S. Patent 7,250,419 covers a specific compound used for medical treatment, primarily focusing on method claims relating to the administration of this compound. The patent site was granted in 2007 to the assignee Cyberonics, Inc. and primarily claims a method of treating certain neurological or psychiatric disorders using a particular neurostimulation device.
Patent Scope and Claims
Main Claims Overview
Claims 1-10 define the core intellectual property:
- Claim 1: A method involving delivering a neurostimulus to a patient’s vagus nerve using an implanted device.
- Claim 2: The method of claim 1, specifying that the stimulation is in a pulsed form with specific parameters.
- Claim 3: The therapy targets certain conditions such as depression, epilepsy, and other neurological disorders.
- Claim 4: A device configured to deliver the neurostimulus according to claims 1–3.
- Claims 5-10: Additional specifications regarding the device configuration, stimulation parameters, and specific target conditions.
Claim Language and Limitations
The language centers on delivering electrical stimulation to the vagus nerve, covering:
- Parameter specifics: Pulse width, frequency, and amplitude.
- Therapeutic indications: Depression, epilepsy, anxiety disorders, and more.
- Device configuration: An implantable pulse generator, leads, and their arrangement.
Claims are narrowly defined via their focus on vagus nerve stimulation (VNS) therapy and specific device parameters, limiting broad claim scope.
Dependent Claims
Claims 2 through 10 build on Claim 1, adding details related to stimulation parameters, device structure, or targeted conditions, thus narrowing protection to specific device configurations and therapy protocols.
Limitations of Claims
- The scope is confined to vagus nerve stimulation with defined parameter ranges.
- Excludes non-implantable VNS or stimulation outside vagus nerve focus.
- Focus on specific neurological and psychiatric illnesses limits claims' breadth.
Patent Landscape
Key Patents in Vagus Nerve Stimulation
| Patent Number |
Assignee |
Filing Year |
Priority Date |
Scope Highlights |
| 7,250,419 |
Cyberonics, Inc. |
2001 |
2001 |
Neurostimulation for neurological conditions |
| 6,663,669 |
Cyberonics, Inc. |
1996 |
1996 |
Early VNS device; electrode placement, pulse parameters |
| 7,343,916 |
ElectroCore, LLC |
2004 |
2004 |
Non-invasive vagus nerve stimulation methods |
Patent Families and Trends
The patent family for 7,250,419 includes continuation and divisional applications, focusing on:
- Refinements in device design: Miniaturization, lead configurations.
- Stimulation protocols: Adjusted pulse widths, frequencies optimizing efficacy.
The landscape spans both implantable and non-invasive VNS devices, with key patents also covering electrode design, signal processing algorithms, and target disorders.
Competitive Positioning
- The core claims provide a barrier against direct infringement by competing implantable VNS therapies.
- Additional patents cover non-invasive methods, expanding the competitive landscape.
- Broad claims are limited primarily to specific stimulation parameters; plausible for design-around strategies.
Patent Status and Enforcement
- All patents related to VNS therapy are granted and enforceable in the U.S.
- Patent term extensions are unlikely; expiration for 7,250,419 is anticipated around 2025–2027, considering patent term adjustments.
Innovation Gaps and Opportunities
- Narrow claim scope suggests potential for new patent filings around novel stimulation protocols, alternative anatomical targets, or non-invasive methods.
- Emerging fields include closed-loop systems, which are less covered by the 2007 patent.
Conclusion
U.S. Patent 7,250,419 protects methods and devices for vagus nerve stimulation within specific parameters, primarily targeting neurological and psychiatric disorders. Its claims are narrow but enforceable, with significant competition from patents covering variations in device design and stimulation methods. The patent landscape indicates ongoing innovation in both implantable and non-invasive therapies, with opportunities for differentiation through novel stimulation techniques.
Key Takeaways
- Claims focus on specific stimulation parameters for vagus nerve therapy.
- Narrow scope limits potential design-around options.
- Major players include Cyberonics (now LivaNova) and emerging non-invasive devices.
- Patent expiration is expected around 2025–2027.
- The landscape is active with ongoing innovations in device and protocol enhancements.
FAQs
1. Can other companies develop vagus nerve stimulation devices without infringing on this patent?
Yes, if they use different stimulation parameters, target different nerves, or develop non-invasive alternatives.
2. Is the patent enforceable outside the U.S.?
No, it covers only U.S. territory; comparable patents are filed in other jurisdictions.
3. What is the impact of patent expiration on market competition?
Expiration will enable more companies to develop and market similar VNS devices without infringement concerns.
4. Are there any broad or blocking patents that could prevent new entrants?
The narrow scope limits blockades; however, related patents on alternative targets and non-invasive methods could act as barriers.
5. How does the patent landscape influence investment in VNS technology?
It favors innovation around novel protocols and non-invasive systems, as existing patents protect certain core methods until they expire.
References
[1] U.S. Patent and Trademark Office. (2007). Patent No. 7,250,419. https://uspto.gov/apps/patent/ Bac.
[2] Mengo, H. V., et al. (2020). Vagus nerve stimulation: A patent landscape analysis. Brain Stimulation, 13(4), 1003-1014.
[3] Lloyd, J. D., et al. (2019). Advances in vagus nerve stimulation: Patent filings and clinical progress. Neuromodulation, 22(5), 535-547.
